Has David Faber received payments from drug or device companies?

Yes. Drug and device makers reported $1,954 in general payments to David Faber across 116 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean David Faber did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about David Faber come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

David Faber

Psychiatry · Pelham, ALNPI 1639117740

Payments from drug & device makers

$1,954in general payments, 2019–2025

Across 116 payments — averaging $16.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$391
Takeda Pharmaceuticals U.S.A., Inc.$280
Neos Therapeutics, LP$139
Alkermes, Inc.$134
Shire North American Group Inc$128
Ironshore Pharmaceuticals Inc.$119
plus $763 from 15 others

What the payments were for

Food & beverage$1,954100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	32	$391
Takeda Pharmaceuticals U.S.A., Inc.	13	$280
Neos Therapeutics, LP	7	$139
Alkermes, Inc.	3	$134
Shire North American Group Inc	10	$128
Ironshore Pharmaceuticals Inc.	6	$119
Johnson & Johnson	8	$113
Teva Pharmaceuticals USA, Inc.	6	$85
Indivior Inc.	4	$83
Tris Pharma Inc	5	$81
Orexo US, Inc.	4	$79
Otsuka America Pharmaceutical, Inc.	4	$61
Adlon Therapeutics L.p.	2	$46
Lundbeck LLC	2	$38
Neurocrine Biosciences, Inc.	2	$36
Avanir Pharmaceuticals, Inc.	2	$35
Eisai Inc.	2	$29
Vertical Pharmaceuticals, LLC	1	$27
Vanda Pharmaceuticals Inc.	1	$22
Supernus Pharmaceuticals, Inc.	1	$16
Rhodes Pharmaceuticals L.p.	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

VIVITROL$106

How this compares

$1,954 in reported general payments places this provider in the 65th percentile of 400 psychiatry providers in Alabama.

See all psychiatry providers in Alabama →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine	38	$1,147
Alprazolam	159	$774
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine	11	$610
Clonazepam	118	$501
Lorazepam	49	$314
Zolpidem Tartrate	29	$261
Gabapentin	23	$248
Diazepam	46	$188
Risperidone	11	$132

Paid to pharmacies, not to this prescriber.

Other psychiatry in Pelham

Annie AndrewsPelham$5K
Matthew MacalusoBirmingham$2.8M
Richard SheltonBirmingham$2.4M
Michael FalolaTrussville$2.2M
Armand SchachterBirmingham$758K
Stephen HughesBirmingham$683K
Leesha Ellis CoxBirmingham$653K
Godehard OepenBirmingham$516K
Lori DavisTuscaloosa$515K
Scariya KumaramangalamHuntsville$440K

See the full list for Alabama →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →